Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-EU long-term Livmarli safety and outcomes study
2024-516804-40-00Phase 4Unknown
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, open-label trial of maralixibat in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) (3 cohorts), sponsored by Mirum Pharmaceuticals, Inc. Status: unknown.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on 2024-516804-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516804-40-00.